CalciMedica, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CALC research report →
Range $14 – $392
Price Chart
About the company
CalciMedica, Inc. , a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions.
- CEO
- A. Rachel Leheny
- IPO
- 2023
- Employees
- 15
- HQ
- La Jolla, CA, US
Get TickerSpark's AI analysis on CALC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.69M
- P/E
- -0.22
- PEG
- 0.06
- P/S
- 0.00
- P/B
- 0.92
- EV/EBITDA
- 0.70
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 3398.40%
- ROIC
- -122.56%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-46,000+0.0%
- Op Income
- $-23,121,000
- Net Income
- $-29,562,000-115.8%
- EPS
- $-9.85-61.5%
- OCF Growth
- -0.2%
- FCF Growth
- -0.2%
- 52W High
- $36.00
- 52W Low
- $1.42
- 50D MA
- $2.62
- 200D MA
- $6.68
- Beta
- 1.12
- RSI (14)
- 26
- Avg Volume
- 72.20K
No earnings-call transcripts are available for CALC yet.
- Free Float
- 109.8%
- Shares Outstanding
- 3.15M
- Float Shares
- 3.46M
of shares held by institutions
28 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Woodline Partners LP | 2.49M | ▲ 2.49M |
| Heights Capital Management, Inc | 1.56M | ▲ 1.56M |
| Stempoint Capital LP | 1.24M | ▲ 1.24M |
| Squadron Capital Management LLC | 1.24M | ▲ 1.24M |
| Stonepine Capital Management, LLC | 622.43K | ▲ 622.43K |
| Vanguard Group Inc | 407.80K | ▲ 31.18K |
| L1 Global Manager Pty Ltd | 248.97K | ▲ 248.97K |
| Morgan Stanley | 143.25K | ▲ 143.25K |
| Geode Capital Management, LLC | 110.48K | ▼ 12.90K |
| Renaissance Technologies LLC | 97.30K | ▼ 30.77K |
| Vanguard Capital Management LLC | 88.96K | ▼ 80.15K |
| 180 Wealth Advisors, LLC | 83.40K | ▼ 43.10K |
Held by 7 ETFs
Biggest fund positions in CALC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Glicklich Alan | other | 20,000 |
| Oct 1, 26 | Zaytsev Evgeny | other | 20,000 |
| Oct 1, 26 | Guerard Frederic | other | 20,000 |
| Oct 1, 26 | Shaw Allan | other | 20,000 |
| Oct 1, 26 | WILSON ROBERT N | other | 20,000 |
| Sep 24, 26 | Hebbar Sudarshan | other | 180,000 |
| Sep 24, 26 | Stauderman Kenneth A. | other | 180,000 |
| Sep 24, 26 | Bardin Stephen | other | 190,000 |
| Sep 24, 26 | Leheny A. Rachel | other | 360,000 |
| Aug 19, 26 | ALAFI CAPITAL CO LLC | other | 3,529,192 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CALC coverage
Recent articles, reports, and earnings notes.
No research on CALC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CALC report →CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 8
CalciMedica Announces One-for-Five Reverse Stock Split
globenewswire.com · Aug 27
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
prnewswire.com · Jul 29
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
prnewswire.com · Jun 24
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
prnewswire.com · Jun 24
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
prnewswire.com · May 12
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
prnewswire.com · Mar 3
CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis
benzinga.com · Jan 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.